Osteoarthritis Claim Should Require Both Knee And Hip Data - Arthritis Cmte.

FDA should require osteoarthritis compounds to be studied in both the knee and hip before granting approval for an overall osteoarthritis claim, FDA's Arthritis Advisory Committee said July 21.